Cargando…

M40. ECT VERSUS SHAM FOR CLOZAPINE RESISTANT SCHIZOPHRENIA: A SECONDARY ANALYSIS OF A PILOT STUDY BASED ON PANSS-30 FACTOR ANALYTIC DIMENSIONS AND THE PANSS-6

BACKGROUND: About 40% of patients with Treatment-Resistant Schizophrenia (TRS) do not respond to an adequate trial with clozapine and are termed Clozapine- Resistant Schizophrenia (CRS). A metanalysis showed that clozapine augmentation with ECT is efficacious for CRS, but no studies with Sham-ECT we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luciana Melzer-Ribeiro, Debora, Cristina Oliveira Solis, Ana, Cistina Grilli Tissot, Maria, Elkis, Helio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233989/ http://dx.doi.org/10.1093/schbul/sbaa030.352

Ejemplares similares

M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2020)

M42. INDEPENDENT REVIEW & MONITORING IMPROVES QUALITY OF PANSS DATA IN GLOBAL CLINICAL TRIALS
por: Echevarria, Barbara, et al.
Publicado: (2020)

M35. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6)
por: Kølbæk, Pernille, et al.
Publicado: (2020)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
por: Hieronymus, Fredrik, et al.
Publicado: (2021)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

Is the PANSS used correctly? a systematic review
por: Obermeier, Michael, et al.
Publicado: (2011)

S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
por: Kaliuzhna, Mariia, et al.
Publicado: (2020)

S37. CROSS-CULTURAL DIFFERENCES IN PANSS ITEM RATINGS: COMPARISONS OF SIX GEO-CULTURAL REGIONS
por: Crittenden, Kia, et al.
Publicado: (2020)

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
por: Lefort-Besnard, Jérémy, et al.
Publicado: (2018)

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
por: Sharafi, Mohammad
Publicado: (2005)

T12. THE RELATIONSHIP OF INTESTINAL PERMEABILITY FACTORS WITH SOCIODEMOGRAPHIC AND PHYSICAL HEALTH FACTORS AND PANSS SCORES IN SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS
por: Borkent, Jenny, et al.
Publicado: (2020)

T56. AN EXPLORATORY ANALYSIS CONVERTING SCORES BETWEEN THE PANSS AND BNSS
por: Kott, Alan, et al.
Publicado: (2018)

S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Ostergaard, Soren Dinesen, et al.
Publicado: (2018)

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2019)

T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY
por: Khan, Anzalee, et al.
Publicado: (2018)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

S118. CAN THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) DIFFERENTIATE REFRACTORY FROM NON-REFRACTORY SCHIZOPHRENIA? A FACTOR ANALYTIC INVESTIGATION BASED ON DATA FROM THE PATTERN COHORT STUDY
por: de Freitas, Rosana, et al.
Publicado: (2018)

S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS
por: Hansen, Johanna, et al.
Publicado: (2020)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
por: Huang, Jiang, et al.
Publicado: (2021)

The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender
por: Sulejmanpasic, Gorana, et al.
Publicado: (2023)

Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)?
por: Nielsen, Cecilie Marie, et al.
Publicado: (2023)

M245. AN RCT PROTOCOL OF HYBRID-ECT FOR SCHIZOPHRENIA
por: Rong, Han
Publicado: (2020)

Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
por: Pinna, Federica, et al.
Publicado: (2014)

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
por: Krekels, EHJ, et al.
Publicado: (2017)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
por: Kølbæk, P., et al.
Publicado: (2021)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses
por: Zeller, Scott, et al.
Publicado: (2017)

M161. NEURAL CHANGES INDUCED BY ELECTROCONVULSIVE THERAPY (ECT) IN SCHIZOPHRENIA PATIENTS: A SYSTEMATIC REVIEW
por: Moon, Sun-Young, et al.
Publicado: (2020)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

M215. FACTORS ASSOCIATED WITH CLOZAPINE RESPONSE AND RESISTANCE IN SCHIZOPHRENIA
por: Lee, Jimmy, et al.
Publicado: (2020)

Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia
por: Jerrell, Jeanette M., et al.
Publicado: (2013)

The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS)
por: Lestari, Endah Tri, et al.
Publicado: (2018)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials
por: Podichetty, Jagdeep T., et al.
Publicado: (2021)

Changes in neurotransmitter levels, brain structural characteristics, and their correlation with PANSS scores in patients with first-episode schizophrenia
por: Xu, Xian-Jia, et al.
Publicado: (2023)

Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials
por: Hieronymus, Fredrik, et al.
Publicado: (2023)

M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA
por: Amoretti, Silvia, et al.
Publicado: (2020)

M138. THE STRUCTURAL AND FUNCTIONAL BRAIN IMPACT OF CLOZAPINE IN SCHIZOPHRENIC PATIENTS: REVIEW OF THE LITERATURE
por: Metivier, Lucie, et al.
Publicado: (2020)

The Interaction of Polymorphisms of IL10 and DBH Was Associated with General Symptoms of PANSS with TD in Chinese Han Schizophrenic Patients
por: Sun, Hongqiang, et al.
Publicado: (2013)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4o8f6075kpn7tncq38f324d95v